Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 606752, 7 pages
http://dx.doi.org/10.1155/2015/606752
Clinical Study

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma

Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tiyuanbei, Huanhuxi Road, Hexi District, Tianjin 300060, China

Received 25 June 2014; Accepted 16 September 2014

Academic Editor: Shiwu Zhang

Copyright © 2015 Zhengzi Qian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Zhengzi Qian, Zheng Song, Huilai Zhang, Xianhuo Wang, Jing Zhao, and Huaqing Wang, “Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma,” BioMed Research International, vol. 2015, Article ID 606752, 7 pages, 2015. https://doi.org/10.1155/2015/606752.